Fact Sheets (English)

Information about bladder cancer and Blue Light Cystoscopy with Hexvix® and Cysview®.

  • About Bladder Cancer

    Bladder cancer ranks as the ninth most common cancer worldwide with 430 000 new cases and more than 165 000 deaths annually. Approx. 75% of all bladder cancer cases occur in men. Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple follow-ups with cystoscopy due to the high risk of recurrence. Bladder cancer has the highest lifetime treatment costs per patient of all cancers. The most common symptom is blood in the urine. Cigarette smoking is the most important risk factor. Early detection is key for successful treatment and survival.

  • About Blue Light Cystoscopy with Hexvix®/Cysview®

    Hexvix®/Cysview® is a drug that is selectively taken up by cancer cells in the bladder making them glow bright pink and easily visible during a cystoscopy. The procedure is preformed with a Blue Light enabled cystoscope. Using BLCTM improves the detection of tumors and leads to more complete removal, less residual tumors and better management decisions.

    Cysview® is the tradename in the US and Canada, Hexvix® is the tradename in all other markets.